Chad Robins, CEO of Adaptive Biotechnology.
Anjali Sundaram CNBC
Ark Invest analyst Simon Barnett on Monday explained the company’s approach to what it calls the genomic revolution, breaking down two of its preferred holdings: Adaptive Biotechnologies and Invitae.
In an interview with CNBC’s Closing Bell, Barnett said Cath Invest, led by Cathie Wood, sees great potential for investors in the field of molecular biology known as genomics, calling it “one of the most transformative opportunities.” investment of the century ”.
Ark’s fund family includes the Genomic Revolution ETF (ARKG), which seeks to provide investors with exposure to areas such as DNA sequencing technology and molecular diagnostics.
The ARKG has fallen by about 7% so far.
However, in the last 12 months, the ETF has increased by about 160%. The company’s flagship fund is the Ark Innovation ETF (ARKK), which has fallen by about 1.6% so far in 2021. ARKK has also risen by almost 160% in the last 12 months.